Brainomix Announces Khush F. Mehta as Chair of the Board
Brainomix, a leader in AI-driven imaging solutions for stroke and lung fibrosis, has appointed Khush F. Mehta as its new Chair of the Board. This move comes as the company looks to further its global outreach and enhance its strategic initiatives.
Khush F. Mehta: A Proven Leader in Healthcare
Khush brings over twenty years of leadership experience in the healthcare sector to Brainomix. Prior to his appointment, he served as the Chairman of Arterys, an AI pioneer in medical imaging, which was acquired by Tempus AI. His rich background includes executive positions such as Chief Strategy Officer at Siemens Healthcare, where he managed operations across Asia Pacific and held key leadership roles in the United States and Germany. Khush's academic credentials are impressive, boasting an MBA from Yale School of Management and a Master’s in Commerce and Financial Management from Sydenham College.
Supporting Global Expansion
Now based in the U.S., Khush is set to assist Brainomix in its internationalization efforts, particularly in the U.S. market, as the company aims to broaden its AI imaging solutions that cater to stroke and lung fibrosis.
Investment and Growth Opportunities
This appointment comes alongside a significant £14M investment, equating to approximately $18M, aimed at accelerating the commercialization of Brainomix's stroke platform both nationally and internationally. The recent acquisition of a pivotal FDA clearance for an innovative feature within the Brainomix 360 platform positions the company as a frontrunner in AI imaging.
Leadership Insight
Dr. Michalis Papadakis, CEO and Co-Founder of Brainomix, expressed his enthusiasm about Khush's appointment. He stated, “Khush’s extensive international experience and expertise in healthcare AI will be instrumental as we continue to expand globally. His leadership is expected to significantly impact our mission of enhancing patient outcomes.”
Reflecting on the transition, Dr. Papadakis noted the valuable mentorship provided by outgoing Chair, Jackie Hunter CBE, during critical phases of growth. Under Jackie's leadership, Brainomix more than doubled its scale, achieving ambitious goals to expand its stroke care offerings while advancing its e-Lung platform.
Forward-Thinking Vision
Expressing his excitement, Khush stated, “Brainomix has developed one of the most effective AI platforms, demonstrating a substantial impact on stroke care with real-world data. I'm honored to guide the company into its next phase of growth and geographic expansion.”
Farewell to Outgoing Chair
Professor Jackie Hunter CBE praised the past five years as a transformative period for Brainomix. She highlighted the company's growth trajectory from a startup to an established scale-up, emphasizing the clinical adoption of their Brainomix 360 Stroke tool and partnerships with leading global pharmaceutical firms.
Andrew Barker, the first Chair of Brainomix, has stepped down from the Board following significant contributions to the company's transition from an academic spinout to a thriving enterprise.
About Brainomix
Brainomix, originating as a spinout from the University of Oxford, specializes in AI-powered software aimed at precision medicine for stroke and lung fibrosis treatment decisions. Operating across over 20 countries, Brainomix has earned accolades for its innovative imaging biomarkers and software solutions, which have been integrated into numerous healthcare institutions worldwide. Its first major product, the Brainomix 360 stroke platform, significantly enhances treatment effectiveness and improves patient independence.
Frequently Asked Questions
Who is the new Chair of Brainomix?
Khush F. Mehta has recently been appointed as the Chair of the Board.
What is the focus of Brainomix?
Brainomix focuses on AI-powered imaging solutions for stroke and lung fibrosis treatment.
Why is the investment important for Brainomix?
The recent £14M investment will accelerate commercial expansion of Brainomix's stroke platform.
What previous roles did Khush F. Mehta hold?
Before joining Brainomix, Khush served as Chairman of Arterys and held key positions at Siemens Healthcare.
How does Brainomix plan to expand?
Brainomix aims to deepen its presence in the U.S. and explore new markets for its AI imaging solutions.
